Lonza takes peptides leadership position via acquisition of UCB-Bioproducts

Swiss chemical and biotechnology company Lonza has completed the acquisition of UCB-Bioproducts in Brussels, Belgium.

Lonza, a global peptide custom manufacturer, purchased the peptide manufacturing division Bioproducts from UCB for Euro 120m. This division, with approximately 300 employees, is located in Braine-l'Alleud just outside Brussels. The site will operate as Lonza Braine, and integration activities will commence immediately.

By uniting the two peptide businesses, Lonza has become the leading and sole contract manufacturer with a historically successful track record of providing Active Pharmaceutical Ingredients (APIs) from any of the three peptide technologies (liquid phase peptide synthesis, solid phase peptide synthesis and recombinant technology).

Lonza is now capable of rapidly providing the market with additional capacity. This acquisition provides Lonza with a site having global reach in peptides, world leading process development and production expertise to serve its customer base. Lonza-Braine complements the other Lonza sites in Visp (Switzerland), Riverside Conshohocken (US) and Kourim (Czech Republic), and enhances significantly customers' sourcing security.